五洲医疗2025年三季报显示，前三季度公司主营收入3.45亿元，同比上升0.82%；归母净利润1850.94万 元，同比下降46.09%；扣非净利润1481.65万元，同比下降45.3%；其中2025年第三季度，公司单季度主 营收入1.28亿元，同比下降1.51%；单季度归母净利润799.43万元，同比下降36.39%；单季度扣非净利 润647.73万元，同比下降28.01%；负债率12.32%，投资收益367.1万元，财务费用-207.28万元，毛利率 14.22%。五洲医疗（301234）主营业务：一次性使用无菌输注类医疗器械的研发、生产、销售以及其 他诊断、护理等相关医疗用品的集成供应,主要通过"ODM+集成供应"的模式满足国外医疗器械品牌商 对医疗用品的一站式采购需求。 资金流向名词解释：指通过价格变化反推资金流向。股价处于上升状态时主动性买单形成的成交额是推 动股价上涨的力量，这部分成交额被定义为资金流入，股价处于下跌状态时主动性卖单产生的的成交额 是推动股价下跌的力量，这部分成交额被定义为资金流出。当天两者的差额即是当天两种力量相抵之后 剩下的推动股价上升的净力。通过逐笔交易单成交金额计算主力资金 ...

来源：新浪证券-红岸工作室 2月26日，五洲医疗涨0.02%，成交额3959.40万元，换手率2.35%，总市值28.38亿元。 异动分析 专精特新+医疗器械概念+人民币贬值受益 1、专精特新"小巨人"企业是全国中小企业评定工作中最高等级、最具权威的荣誉称号，是指专注于细 分市场、创新能力强、市场占有率高、掌握关键核心技术、质量效益优的排头兵企业，对于提升中小企 业自身的竞争力，以及提升产业链、供应链稳定性和竞争力具有重大意义。公司已入选工信部专精特新 小巨人企业名单。 2、公司主营业务为一次性使用无菌输注类医疗器械的研发、生产、销售以及其他诊断、护理等相关医 疗用品的集成供应，产品为一次性使用无菌注射器(带针)、一次性使用无菌注射器(不带针)、一次性使 用无菌胰岛素注射器、输液器、输血器、注射针、胰岛素注射笔用针头、输液针、采血针、血压表、面 罩、导尿管。 3、根据2024年年报，公司海外营收占比为96.88%，受益于人民币贬值。 资料显示，安徽宏宇五洲医疗器械股份有限公司位于安徽省安庆市太湖县经济开发区观音路2号，成立 日期2011年4月15日，上市日期2022年7月5日，公司主营业务涉及一次性使用无菌输 ...

证券日报网讯2月25日，五洲医疗（301234）在互动平台回答投资者提问时表示，截至2026年2月13日， 公司股东总户数为5459户。 ...

来源：新浪证券-红岸工作室 2月25日，五洲医疗跌0.45%，成交额2491.21万元，换手率1.48%，总市值28.38亿元。 今日主力净流入-136.64万，占比0.05%，行业排名90/138，连续3日被主力资金减仓；所属行业主力净流 入-2.37亿，连续3日被主力资金减仓。 区间今日近3日近5日近10日近20日主力净流入-136.64万-450.86万-998.01万-1505.18万-2909.72万 主力持仓 异动分析 医疗器械概念+专精特新+人民币贬值受益 1、公司主营业务为一次性使用无菌输注类医疗器械的研发、生产、销售以及其他诊断、护理等相关医 疗用品的集成供应，产品为一次性使用无菌注射器(带针)、一次性使用无菌注射器(不带针)、一次性使 用无菌胰岛素注射器、输液器、输血器、注射针、胰岛素注射笔用针头、输液针、采血针、血压表、面 罩、导尿管。 2、专精特新"小巨人"企业是全国中小企业评定工作中最高等级、最具权威的荣誉称号，是指专注于细 分市场、创新能力强、市场占有率高、掌握关键核心技术、质量效益优的排头兵企业，对于提升中小企 业自身的竞争力，以及提升产业链、供应链稳定性和竞争力具有重大意义。公 ...

Core Viewpoint - Wuzhou Medical has been recognized as a "specialized, refined, distinctive, and innovative" enterprise, which is a prestigious title for small and medium-sized enterprises in China, indicating its strong market position and innovation capabilities [2]. Group 1: Company Overview - Wuzhou Medical specializes in the research, production, and sales of disposable sterile infusion medical devices and related medical supplies, including various types of syringes, infusion sets, and other medical instruments [2][7]. - The company was established on April 15, 2011, and went public on July 5, 2022, with its headquarters located in Anqing, Anhui Province [7]. - The revenue composition of Wuzhou Medical includes 41.29% from syringes, 25.51% from medical puncture needles, 20.92% from infusion and blood transfusion devices, and 12.28% from other products [7]. Group 2: Financial Performance - For the period from January to September 2025, Wuzhou Medical achieved a revenue of 345 million yuan, representing a year-on-year growth of 0.82%, while the net profit attributable to the parent company was 18.51 million yuan, a decrease of 46.09% year-on-year [7]. - The company has distributed a total of 81.6 million yuan in dividends since its A-share listing [8]. Group 3: Market Position and Trends - Wuzhou Medical's overseas revenue accounts for 96.88%, benefiting from the depreciation of the Chinese yuan [3]. - The company is classified under the pharmaceutical and biological industry, specifically in the medical device and consumables sector, and is involved in various concept sectors including medical consumables and overseas expansion [7].

Group 1 - The stock price of Wuzhou Medical (301234) showed volatility from February 4 to February 11, 2026, with a closing price of 42.01 yuan on February 10, reflecting a daily increase of 0.26%, and a latest price of 41.80 yuan on February 11, indicating a decrease of 0.50% [1] - On February 10, the net outflow of main funds was 362.88 thousand yuan, accounting for 14.62% of the total transaction amount, with an overall trend of net outflow in the past five days [1] - The technical indicators show that the current stock price is close to the 20-day resistance level of 42.24 yuan, with a recent MACD indicator showing a golden cross signal, although the distribution of shares is scattered, indicating low control by main funds [1] Group 2 - Recent policies in the medical industry may indirectly impact Wuzhou Medical, with the launch of the China International Medical Equipment and Devices Trading Platform on February 10, aimed at promoting global trade in medical devices, which could benefit the company as its overseas revenue accounts for 96.88% based on the 2024 annual report [2] - The Ministry of Industry and Information Technology and other departments have strengthened policy support for low-altitude economy and AI medical fields, although the company's business is not directly involved in these hot concepts [2] Group 3 - Wuzhou Medical released its 2025 annual performance forecast on January 29, 2026, expecting a net profit range of 16 million to 21 million yuan, representing a year-on-year decline of 47.46% to 59.97%, primarily due to fluctuations in its main business [3] - The company's third-quarter report for 2025 indicated a year-on-year decrease of 46.09% in net profit attributable to the parent company [3]

Core Viewpoint - Wuzhou Medical (301234) reported a slight increase in stock price but faced significant declines in net profit and net profit after deducting non-recurring items in the latest financial results [1][2]. Financial Performance - For the first three quarters of 2025, Wuzhou Medical achieved a main operating revenue of 345 million yuan, a year-on-year increase of 0.82% [2]. - The net profit attributable to shareholders was 18.51 million yuan, reflecting a year-on-year decrease of 46.09% [2]. - The net profit after deducting non-recurring items was 14.82 million yuan, down 45.3% year-on-year [2]. - In Q3 2025, the company reported a single-quarter main operating revenue of 128 million yuan, a decline of 1.51% year-on-year [2]. - The single-quarter net profit attributable to shareholders was 7.99 million yuan, down 36.39% year-on-year [2]. - The single-quarter net profit after deducting non-recurring items was 6.48 million yuan, a decrease of 28.01% year-on-year [2]. - The company's debt ratio stood at 12.32%, with investment income of 3.67 million yuan and financial expenses of -2.07 million yuan [2]. - The gross profit margin was reported at 14.22% [2]. Business Model - Wuzhou Medical specializes in the research, production, and sales of disposable sterile infusion medical devices, as well as integrated supply of other diagnostic and nursing medical supplies [2]. - The company primarily operates through an "ODM + integrated supply" model to meet the one-stop procurement needs of foreign medical device brand companies [2].

Core Viewpoint - Wuzhou Medical has shown a slight increase in stock price and is recognized as a "specialized, refined, distinctive, and innovative" enterprise, benefiting from the depreciation of the RMB and a strong overseas revenue stream [2][3]. Group 1: Company Overview - Wuzhou Medical specializes in the research, production, and sales of disposable sterile infusion medical devices and related medical supplies, with a product range that includes various types of syringes, infusion sets, and other medical instruments [2][7]. - The company was established on April 15, 2011, and went public on July 5, 2022, with a current market capitalization of 2.857 billion yuan [1][7]. - As of January 20, the number of shareholders is 5,364, a decrease of 2.28%, with an average of 7,488 circulating shares per person, an increase of 2.33% [7]. Group 2: Financial Performance - For the period from January to September 2025, Wuzhou Medical achieved a revenue of 345 million yuan, representing a year-on-year growth of 0.82%, while the net profit attributable to the parent company was 18.51 million yuan, a decrease of 46.09% year-on-year [7]. - The company has distributed a total of 81.6 million yuan in dividends since its A-share listing [8]. Group 3: Market Position and Trends - Wuzhou Medical's overseas revenue accounts for 96.88% of its total revenue, benefiting from the depreciation of the RMB [3]. - The company is recognized as a leader in its niche market, which enhances its competitiveness and stability within the supply chain [2].

Group 1 - The core viewpoint of the news is that Wuzhou Medical (301234) has shown a slight increase in stock price, with a closing price of 41.9 yuan on February 9, 2026, reflecting a 1.4% rise [1] - The company reported a main revenue of 345 million yuan for the first three quarters of 2025, representing a year-on-year increase of 0.82% [2] - The net profit attributable to the parent company for the same period was 18.51 million yuan, showing a significant year-on-year decline of 46.09% [2] Group 2 - In the third quarter of 2025, the company's single-quarter main revenue was 128 million yuan, which is a year-on-year decrease of 1.51% [2] - The net profit attributable to the parent company for the third quarter was 7.99 million yuan, down 36.39% year-on-year [2] - The company's debt ratio stands at 12.32%, with an investment income of 3.67 million yuan and a financial expense of -2.07 million yuan [2] Group 3 - The company operates in the field of research, production, and sales of disposable sterile infusion medical devices, primarily using an "ODM + integrated supply" model to meet the one-stop procurement needs of foreign medical device brand owners [2] - The gross profit margin for the company is reported at 14.22% [2] Group 4 - On February 9, 2026, the net inflow of main funds was 762,700 yuan, accounting for 2.21% of the total transaction amount [1] - Retail investors saw a net inflow of 1.40 million yuan, representing 4.06% of the total transaction amount, while speculative funds experienced a net outflow of 2.17 million yuan, which is 6.27% of the total transaction amount [1]

Core Viewpoint - Wuzhou Medical has shown a slight increase in stock price and is benefiting from the depreciation of the RMB, with a significant portion of its revenue coming from overseas sales [1][3]. Group 1: Company Overview - Wuzhou Medical specializes in the research, production, and sales of disposable sterile infusion medical devices, including various types of syringes, infusion sets, and other medical supplies [2]. - The company has been recognized as a "specialized, refined, distinctive, and innovative" small giant enterprise, indicating its strong market position and innovation capabilities [2]. - As of January 20, the company reported a revenue of 345 million yuan for the first nine months of 2025, reflecting a year-on-year growth of 0.82%, while net profit decreased by 46.09% to approximately 18.51 million yuan [7]. Group 2: Financial Performance - The company's overseas revenue accounts for 96.88% of total revenue, benefiting from the depreciation of the RMB [3]. - The average trading cost of the stock is 42.76 yuan, with the current price near a support level of 41.29 yuan, indicating potential volatility [6]. - The company has distributed a total of 81.6 million yuan in dividends since its A-share listing [8]. Group 3: Market Position and Shareholder Information - Wuzhou Medical operates under the pharmaceutical and medical device industry, focusing on medical consumables [7]. - As of September 30, 2025, the company saw a decrease in the number of shareholders by 2.28%, with an increase in average circulating shares per person by 2.33% [7][9].